WHAT HAS CHANGED FROM THE ORIGINAL IMRALDI™
The volume of the solution in Imraldi™ pen or pre-filled syringe is lower due to the high concentration formulation – 0.4 ml instead of the previous 0.8 ml.
New formulation of Imraldi™ does not include citrate.
For some patients the injection experience might be more comfortable due to the updated citrate-free formulation with a lower volume.
Imraldi™ has out of the fridge stability for 31 days at temperatures up to a maximum of 25°C.†1 This is an increase of 3 days as compared with the previous Imraldi™ formulation.
lnjection window in the Imraldi™ pen is now smaller and your lmraldi™ syringe is shorter.

The syringe or pen must be protected from light, and discarded if not used within the 31-day period.

WHAT REMAINS THE SAME AS THE ORIGINAL IMRALDI
One injection of Imraldi™ contains the same dose of the same active ingredient adalimumab.
The effectiveness of lmraldi™ remains comparable as it contains the same active ingredient.
Side effects due to the mode of action, as the active ingredient is still the same.
There is no change in the way your patient will administer the medicine.